Page last updated: 2024-12-08

(RS)-coclaurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(RS)-Coclaurine is a **naturally occurring benzylisoquinoline alkaloid**. It is found in various plants, including:

* **Corydalis species:** These are flowering plants that belong to the poppy family. They are a significant source of (RS)-coclaurine.
* **Stephania species:** These are climbing plants also belonging to the Menispermaceae family.

**Why is (RS)-Coclaurine Important for Research?**

(RS)-Coclaurine has garnered significant research interest due to its **potential pharmacological activities**:

* **Antioxidant:** It demonstrates potent antioxidant properties, scavenging free radicals and protecting cells from oxidative stress. This may be valuable in preventing various diseases associated with oxidative damage, such as cancer and neurodegenerative disorders.
* **Anti-inflammatory:** (RS)-Coclaurine exhibits anti-inflammatory effects, potentially by inhibiting inflammatory mediators like cytokines. This suggests its potential use in treating inflammatory conditions, including arthritis and inflammatory bowel disease.
* **Anti-cancer:** Studies have shown (RS)-coclaurine's potential anti-cancer activity. It has been found to inhibit the growth and proliferation of cancer cells in various studies.
* **Neuroprotective:** There is growing evidence that (RS)-coclaurine may have neuroprotective effects, protecting nerve cells from damage caused by various factors, including oxidative stress and neurotoxins. This could be relevant in treating neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Anti-viral:** Some research suggests that (RS)-coclaurine may possess antiviral activity, potentially inhibiting the replication of certain viruses. This is an exciting area of investigation, especially in the context of emerging viral threats.

**Research Focus:**

Current research focuses on:

* **Exploring the mechanisms of action:** Elucidating how (RS)-coclaurine exerts its various pharmacological effects is crucial to understanding its potential therapeutic applications.
* **Developing new therapeutic agents:** Research aims to develop novel drugs based on (RS)-coclaurine or its derivatives, harnessing its therapeutic potential for various diseases.
* **Investigating its safety and efficacy:** Further studies are needed to assess the safety and efficacy of (RS)-coclaurine in humans before it can be used clinically.

**Note:** While promising, it's essential to remember that much of the research on (RS)-coclaurine is still in its early stages. Further research is required to confirm its therapeutic potential and ensure its safety for human use.

Cross-References

ID SourceID
PubMed CID281691
CHEMBL ID453291
CHEBI ID18417
SCHEMBL ID1901279

Synonyms (27)

Synonym
1-[(4-hydroxyphenyl)-methyl]-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-7-ol
nsc134560
15548-30-8
nsc-134560
1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
(rs)-coclaurine
CHEBI:18417 ,
MLS000574945
smr000156307
6-methoxy-7-hydroxy-1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
C06348
(r,s)-coclaurine
dl-coclaurine
CHEMBL453291
1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
NCGC00247618-01
SCHEMBL1901279
HMS2208L14
HMS3342D16
LVVKXRQZSRUVPY-UHFFFAOYSA-N
isoquinolin-7-ol, 1-[4-hydroxybenzyl]-1,2,3,4-tetrahydro-6-methoxy-
1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydro-7-isoquinolinol #
bdbm50478458
Q27103066
BCP28302
FT-0777374
DTXSID20871678
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coclaurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
glucocerebrosidaseHomo sapiens (human)Potency14.12540.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
pyruvate kinase PKM isoform aHomo sapiens (human)Potency25.11890.04017.459031.6228AID1631; AID1634
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.83260.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.58050.004611.374133.4983AID624296
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID354885Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/ml by turbidimetric method1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID354888Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/ml by turbidimetric method1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID354882Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/ml by turbidimetric method1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID354891Inhibition of platelet-activity factor-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/ml by turbidimetric method1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID354902Vasorelaxant activity against norepinephrine-induced tonic contraction in Wistar rat thoracic aorta at 100 ug/ml1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID356082Displacement of [3H]diltiazem from benzodiazepine binding site of L-type calcium channel in Wistar rat cerebral cortex membrane2003Journal of natural products, Jul, Volume: 66, Issue:7
Simplified tetrandrine congeners as possible antihypertensive agents with a dual mechanism of action.
AID356083Vasorelaxant activity against noradrenaline-induced contraction in Wistar rat thoracic aorta in presence of calcium2003Journal of natural products, Jul, Volume: 66, Issue:7
Simplified tetrandrine congeners as possible antihypertensive agents with a dual mechanism of action.
AID356081Displacement of [3H]prazosin from alpha1 adrenergic receptor in Wistar rat cerebral cortex membrane2003Journal of natural products, Jul, Volume: 66, Issue:7
Simplified tetrandrine congeners as possible antihypertensive agents with a dual mechanism of action.
AID356085Vasorelaxant activity against KCl-induced contraction in Wistar rat thoracic aorta at 100 uM in presence of calcium2003Journal of natural products, Jul, Volume: 66, Issue:7
Simplified tetrandrine congeners as possible antihypertensive agents with a dual mechanism of action.
AID354894Vasorelaxant activity against high potassium-induced contraction in Wistar rat thoracic aorta at 100 ug/ml1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID354898Vasorelaxant activity against norepinephrine-induced phasic contraction in Wistar rat thoracic aorta at 100 ug/ml1996Journal of natural products, May, Volume: 59, Issue:5
Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.70 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]